Real-world Clinical Outcomes of Patients With Early-stage Lung Cancer After the Surgery
About this study
The goal of this observational study is to evaluate the efficacy and long-term clinical outcomes of early-stage lung cancer patients who have received surgery using the real-world data. The main questions it aims to answer are: * What is the best surgical strategy for patients with early-stage lung cancer? * What are the risk factors for early-stage lung cancer? Participants will receive surgery and the study will analyze the real-world data.
- Condition
- Lung Cancer
- Tested
- Sublobar resection, Lobectomy
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Who can join
- Age
- 18 to 85 years
- Sex
- All sexes
- Healthy volunteers
- Not stated
Inclusion 10
- Minimum age: 18 years
- Maximum age: 85 years
- Study condition: Lung Cancer
- Aged between 18 and 85;
- Did not receive neoadjuvant therapy before surgery;
- No history of radiation therapy;
- Eastern Cooperative Oncology Group (ECOG) score is 0-1;
- Have complete clinically relevant information including imaging data;
- All patients underwent relevant preoperative examinations;
- Stage I lung cancer (International Association for the Study of Lung Cancer/The Union for International Cancer Control staging eighth edition);
Exclusion 2
- Have previously received chemotherapy, radiotherapy and other anti-tumor therapy;
- Data loss and error in medical records due to human/objective reasons.
Where
1 site, 1 recruiting
Shugeng Gao
Beijing, Beijing Municipality, China
Contact
-
Shugeng Gao, MD
8610-87788177 gaoshugeng@cicams.ac.cn
Potential match only. Final eligibility is determined by the study team.